

## APPENDIX 6 – DENOSUMAB (PROLIA®) INJECTIONS

### 1. BACKGROUND

The administration of denosumab (Prolia®) within primary care is designed to be an enhanced service which allows patients who require treatment to have it prescribed and administered safely, effectively and conveniently close to their home following initial assessment and recommendation by a hospital specialist.

Primary care teams are ideally placed to play a role in the management of patients with osteoporosis<sup>1</sup> and pharmacological intervention forms part of this. Most treatments can be administered in the primary care setting and NICE guidance is available to support appropriate use of available therapies:

- Primary prevention of osteoporosis: [www.nice.org.uk/TA160](http://www.nice.org.uk/TA160)
- Secondary prevention of osteoporosis: <http://guidance.nice.org.uk/TA161>

Denosumab (Prolia®) became available in the UK in May 2010. Denosumab for the treatment of osteoporosis in postmenopausal women has been assessed by NICE under a Single Technology Appraisal (STA) 204 issued (October 2010 (<http://guidance.nice.org.uk/TA204> )

### 2. AIM OF SERVICE

This locally commissioned service will fund:

- The administration and monitoring of denosumab injections for the treatment of osteoporosis in postmenopausal women and men at increased risk of fractures.

### 3. SERVICE DELIVERY

It is a requirement that the contractor of this local commissioned service follows the Shared Care Guideline for denosumab (Prolia®) for the treatment of osteoporosis in postmenopausal women and men at increased risk of fractures, available [here](#). The Shared Care Guideline provides clinical information relating to the administration and monitoring of denosumab treatment. The Shared Care Guideline defines the responsibilities of the hospital specialist, GP, community pharmacist and patient to ensure safe and effective treatment with denosumab (Prolia®). Patients should not stop denosumab (Prolia®) without specialist review due to increased risk of multiple vertebral fractures ([MHRA Drug Safety Update August 2020](#)).

### 4. PRICING

Practices will receive **£52.52 per injection** for administering denosumab injections and for providing the monitoring from the 1<sup>st</sup> injection as outlined in this specification and shared care guideline, in line with the patient's individual treatment plan.

**We do not expect this to be any more than 2 injections per patient per year administered in Primary care**

### 5. REPORTING

The numbers of denosumab injections administered by the Practice in the relevant 6-month period.

Practices are also required to record the following information to be retained at the practice but made available to the Commissioner on request.

- Number of patients currently on the register
- Number of injections performed
- Number of pre injection assessments have been carried out prior to injection
- Name of trained person administering the injection